/PRNewswire/ Neurophth Therapeutics, Inc. ("Neurophth"), a China s leading gene therapy company for ophthalmic diseases, announced the closing of nearly 95.
At least two venture capital firms Nascent and DRW have distanced themselves from OPNX. Earlier today, OPNX revealed that its major investors included…